- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01019551
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)
International, Multicenter, Randomized, Non-comparative Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The overall strategy of the ERAMUNE 01 Trial is to treat selected patients with an optimal synergistic antiretroviral regimen plus one or more immunomodulating agents. Among immunomodulating treatments the candidates include therapies from two functional classes: 1) agents that target actively replicating cells and 2) agents activating latently infected cells31.
The novelty of this approach is three-fold: first, the use of highly potent antiretroviral therapy combining drugs with different HIV enzymes targets or receptors and different penetrations in cells, with the aim to suppress virus to truly undetectable levels as measured by the most sophisticated viral quantification techniques; secondly, the addition of an immunomodulatory therapy that specifically targets viral reservoirs to this intensification strategy; and lastly, the rigorous selection of patients having already a low HIV reservoir as measured by peripheral blood HIV DNA content. To our knowledge, this type of strategy has not been implemented. We believe this strategy is feasible.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Paris, Frankrike, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Milan, Italien, 20127
- San Raffaele Scientific Institute
-
-
-
-
-
Badalona, Spanien, 08916
- Fundacio Irsicaixa
-
Barcelona, Spanien, 08036
- University Hospital Clinic of Barcelona
-
-
-
-
-
London, Storbritannien, NW3 2QG
- Royal Free Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- HIV-1 infection, documented by any licensed ELISA test kit and confirmed by Western Blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
- 18 ≤ Age ≤ 70 years
- At least 3 years of suppressive ART without any interruption (less than one month cumulative),
- ART treatment unchanged in the 3 months prior to screening
- One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at least 2 HIV plasma viral loads (RNA) documented per year thereafter
- HIV plasma viral load (RNA) ≤ 500 copies/ml at least 3 years prior to entry and HIV plasma viral load ≤ 500 copies/ml for ≥ 90% of the measures thereafter
- HIV plasma viral load (RNA) below the limit of detection for all values within the past year. Note: the assay used must have a lower limit of detection of 75 copies/ml or less
- CD4+ count ≥ 350 cells/mm3 within 60 days of entry
- 10 ≤ Proviral DNA ≤ 1000 copies/106 PBMCs within 60 days of entry
- Documented laboratory values: Haemoglobin ≥ 10 g/dl, Platelets ≥ 100,000 per microliter, Hepatic transaminases ≤ 2.5 x ULN, Creatinine clearance ≥ 50 ml/min by the Cockcroft-Gault equation
- All subjects must agree not to participate in the conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the subject/partner must use at least two reliable forms of contraceptives (condoms, with or without spermicidal agent, a diaphragm or cervical cap with spermicide, an IUD, or hormone-based contraception), while receiving study treatment and for 6 weeks after stopping study treatment
- Ability and willingness to provide informed consent.
Exclusion Criteria:
- Sexually active men and women who will not practice at least one form of barrier birth control (male partner using condoms, female partner using condoms, other barrier contraception, etc)
- Pregnancy as documented by a urine pregnancy test, or lactating women
- Hepatitis B antigen (HBsAg) positive
- Hepatitis C virus (HCV-Ab) positive or HCV RNA detectable
- Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie maraviroc, vicriviroc). Use of raltegravir for non-treatment failure indications such as intensification and toxicity switches is allowed, provided that 1) virologic suppression was maintained before, during and after raltegravir treatment and 2) the patient has not received raltegravir treatment in the 6 months prior to study entry.
- Previous immunologic therapeutic intervention (e.g. IL-2, IL-7) within the past year
- Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted
- Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and cutaneous KS not requiring systemic therapy)
- Co-morbid condition with an expected survival less than 12 months
- History of hypersensitivity to vaccination
- History of autoimmune disease, such as systemic lupus erythematosis (SLE) or Hashimoto's thyroiditis
- Active drug or alcohol use or dependence that, in the opinion of the center investigator, would interfere with adherence to study requirements.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: ARM A : ART intensification alone
Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
|
Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
|
Experimentell: ARM B : ART intensification + Immunomodulation
Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
|
Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Decrease from baseline in HIV proviral DNA in the PBMCs at week 56 of at least 0.5 log, as expressed as numbers of HIV DNA copies per million PBMCs
Tidsram: End of study
|
End of study
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Percentage of patients with undetectable HIV DNA (< 1 copy/million PBMCs) after 56 weeks
Tidsram: End of study
|
End of study
|
Change from baseline in HIV proviral DNA in any of the sub-compartments explored (gut lymphoid tissue), as expressed as numbers of HIV DNA copies per million mononuclear cells
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Change from baseline in HIV proviral DNA in the CD4 T cell subsets, as expressed as numbers of HIV DNA copies per million CD4 T cells
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Changes from baseline in HIV plasma viral load (number of copies of HIV RNA per millilitre), measured by quantitative ultrasensitive PCR
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Proportion of patients without inducible HIV RNA, DNA and/or p24
Tidsram: End of study
|
End of study
|
Changes from baseline in CD4 lymphocyte count
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Changes in the activation and differentiation markers of the CD4 and CD8 peripheral blood T cells
Tidsram: End of study
|
End of study
|
Development of a mathematical model exploring the dynamics of the HIV-DNA decay
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Development of a mathematical model exploring the dynamics of T cells activation (CD38)
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Genetic determinants influencing HIV-1-specific immune response and HIV control
Tidsram: End of study
|
End of study
|
Antiretroviral drugs pharmacokinetics in the blood and rectal mucosa
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Safety and tolerability of the intensified treatment regimen and immunomodulatory therapy
Tidsram: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Christine Katlama, MD, Groupe Hospitalier Pitie-Salpetriere
- Studierektor: François LECARDONNEL, MSc, ORVACS
- Studiestol: Steven DEEKS, MD, University of California, San Francisco
Publikationer och användbara länkar
Allmänna publikationer
- Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. A step ahead on the HIV collaboratory. Science. 2009 Jun 5;324(5932):1264-5. doi: 10.1126/science.324_1264b. No abstract available.
- Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS. 2011 Apr 24;25(7):885-97. doi: 10.1097/QAD.0b013e3283467041.
- Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep. 2012 Jun;9(2):121-31. doi: 10.1007/s11904-012-0115-y.
- Cohen J. The emerging race to cure HIV infections. Science. 2011 May 13;332(6031):784-5, 787-9. doi: 10.1126/science.332.6031.784. No abstract available.
- Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.
- Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, Tambussi G, Clotet B, Youle M, Achenbach CJ, Murphy RL, Calvez V, Costagliola D, Autran B; EraMune-01 study team. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS. 2016 Jan;30(2):221-30. doi: 10.1097/QAD.0000000000000894.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- ORVACS 010
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-1-infektion
-
Institut PasteurRekrytering
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... och andra samarbetspartnersAvslutadHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesAvslutad
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaAvslutad
-
Gilead SciencesAvslutad
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry...Avslutad
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-1Förenta staterna, Frankrike, Spanien, Portugal, Kanada, Storbritannien, Sydafrika, Argentina, Brasilien, Puerto Rico, Thailand, Nederländerna, Rumänien
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-1Förenta staterna, Kanada, Frankrike, Belgien, Tyskland, Spanien, Argentina, Chile, Panama, Brasilien, Puerto Rico, Thailand, Mexiko, Australien
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma... och andra samarbetspartnersAvslutad
-
Helios SaludViiV HealthcareOkändHiv | HIV-1-infektionArgentina
Kliniska prövningar på ART Intensification
-
Asahi Kasei Pharma CorporationAvslutadPostoperativ steg II/III tjocktarmscancerJapan
-
Institute of Tropical Medicine, BelgiumUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; Agentschap voor... och andra samarbetspartnersAvslutad
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA); University of Washington; Seattle... och andra samarbetspartnersAvslutad
-
Laboratoires FILLMEDAvslutad
-
Tang-Du HospitalZhejiang University; Chipscreen Biosciences, Ltd.; First Affiliated Hospital...OkändKroniska HIV-infektionerKina
-
Nanyang Technological UniversityNational Gallery SingaporeAnmälan via inbjudanSlow Art Plus: A Single Session Art Gallery-baserad intervention för främjande av mental hälsa (SAP)Medkänsla | Psykisk hälsa 1 | EgenvårdSingapore
-
University of WashingtonBill and Melinda Gates FoundationAvslutadHIV | KONSTSydafrika, Uganda
-
Asahi Kasei Pharma CorporationAvslutadIdiopatisk lungfibrosJapan
-
Na Homolce HospitalCentre of Cardiovascular and Transplantation Surgery, Czech Republic; St... och andra samarbetspartnersRekryteringAortaklaffsuppstötningarSerbien, Tjeckien, Belgien
-
Children's Hospital Medical Center, CincinnatiRekryteringAttention Deficit Hyperactivity DisorderFörenta staterna